FDA approves the higher-dose Ozempic 2 mg pen

On March 28, 2022, the FDA approved a higher-dose 2 mg version of Ozempic (semaglutide), adding a new step to the drug's dosing ladder for adults with type 2 diabetes ^[1]. Ozempic was first approved in December 2017 at lower doses, and the 2 mg option was added later as a way to give patients more room to increase their dose if earlier levels weren't controlling blood sugar well enough ^[1].

According to the prescribing information, patients start at 0.25 mg once weekly for four weeks, then move to 0.5 mg ^[2]. If more glycemic control is needed, the dose can be raised to 1 mg after at least four weeks at 0.5 mg, and then to 2 mg after at least four weeks at the 1 mg dose ^[2]. This step-up approach is meant to let the body adjust and to limit side effects as the dose increases ^[2].

The 2 mg dose comes in an 8 mg/3 mL pen, which delivers four weekly doses of 2 mg each ^[1][2]. This is a separate, higher-strength pen from the ones used for the 0.25 mg, 0.5 mg, and 1 mg doses ^[2]. Ozempic is injected once a week, at any time of day, with or without food, into the abdomen, thigh, or upper arm ^[2].

Ozempic carries a boxed warning about thyroid C-cell tumors, based on findings in rodent studies; it is not known whether the drug causes these tumors in humans ^[2]. The drug is not for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[2]. Other warnings include acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or certain other diabetes drugs, kidney injury from fluid loss, severe stomach and intestinal reactions, serious allergic reactions, gallbladder disease, and a risk of inhaling stomach contents during surgery with general anesthesia ^[2]. The most common side effects reported in at least 5% of patients are nausea, vomiting, diarrhea, stomach pain, and constipation ^[2].

Why it matters for patients

For people with type 2 diabetes already on Ozempic at 0.5 mg or 1 mg, the 2 mg dose gives doctors another option if blood sugar control isn't where it needs to be ^[1]. Because the dose is raised gradually over weeks, patients moving up to 2 mg have typically already been on the drug for some time and are used to how their body responds to it ^[2]. The higher dose does not change how the drug is taken — it's still a once-weekly injection — but it does require a different, higher-strength pen ^[1][2]. Patients switching doses should be aware the warnings and precautions, including the boxed warning about thyroid tumors, apply at every dose level, not just the higher one ^[2].

What happens next

Ozempic's approval history shows a pattern of added indications and formulations over time. The drugs.com timeline lists further approvals after the 2 mg dose, including a January 2020 approval for cardiovascular risk reduction and a January 2025 approval recognizing Ozempic as a treatment to reduce the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease ^[1]. Separately, FDA records show the agency has continued reviewing labeling and manufacturing supplements for Ozempic's application (NDA 209637) in the years since, reflecting ongoing regulatory activity around the drug ^[3].